BioStem Technologies, Inc.
No SEC Form 4 filings for $BSEM in the last 30 days.
See all $BSEM insider activity →BioStem Technologies, Inc. (BSEM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 bsem-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 BioStem Technologies Reports Second Quarter 2026 Financial Results Generates 29% sequential revenue growth, increasing to $7.9 million; Raises full-year 2026 revenue guidance Uplists to Nasdaq Capital Market POMPANO BEACH, FL
BioStem Technologies Inc. (OTC: BSEM) said it filed a Form 10 registration statement with the SEC to register its common stock and reaffirmed plans to pursue a Nasdaq listing. The filing is not yet effective and will become effective after SEC review. Until uplisting, BSEM shares continue trading on the OTC market.
POMPANO BEACH, Fla., April 21, 2025 ( GLOBE NEWSWIRE ) -- BioStem Technologies, Inc. ( OTC: BSEM ) , a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, is pleased to announce that its Chief Executive ...
Over the past 7 days, alphai's AI scored 1 news story mentioning BSEM (BioStem Technologies, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent BSEM coverage spans financial news, earnings and corporate actions.
The 8-K combines an earnings-style datapoint (Q2 revenue and margins), a guidance raise, and a financing/cash update, which can drive near-term repricing and liquidity risk assessment.
The Form 10 filing is a concrete step toward Nasdaq uplisting, but effectiveness is pending SEC review, keeping near-term outcomes uncertain.
BioStem Technologies announced participation in a prominent industry conference, which may positively influence investor sentiment and stock performance.
BioStem Technologies reports record revenue and profitability for 2024, indicating strong operational performance.
alphai scores every news story that mentions BSEM with an AI model for sentiment and relevance, and aggregates insider trades from BioStem Technologies, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BioStem Technologies, Inc. (BSEM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 bsem-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 BioStem Technologies Reports Second Quarter 2026 Financial Results Generates 29% sequential revenue growth, increasing to $7.9 million; Raises full-year 2026 revenue guidance Uplists to Nasdaq Capital Market POMPANO BEACH, FL
4 min readBioStem Technologies Inc. (OTC: BSEM) said it filed a Form 10 registration statement with the SEC to register its common stock and reaffirmed plans to pursue a Nasdaq listing. The filing is not yet effective and will become effective after SEC review. Until uplisting, BSEM shares continue trading on the OTC market.
3 min readPOMPANO BEACH, Fla., April 21, 2025 ( GLOBE NEWSWIRE ) -- BioStem Technologies, Inc. ( OTC: BSEM ) , a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, is pleased to announce that its Chief Executive ...
2 min readCompany reports record preliminary fourth quarter net revenue of $102.9 Million, contributing to a total of $301.8 Million in revenue for 2024 Achieves preliminary GAAP net income of $15.5 million, or $0.94 per share, marking the fourth consecutive quarter of profitability
2 min read
